Glucocorticoid-induced bone loss is the most prevalent form of secondary osteoporosis. Such loss could be due to the alteration of osteoclast and osteoblast lifespan through regulated apoptosis. The current study investigated the effect of dexamethasone on Fas-and starvation-induced apoptosis of mature osteoblasts and their precursors. Using the human osteoblastic hFOBl.19 and the MG63 osteosarcoma cell lines, we found that sub-lethal doses of dexamethasone act on pre-osteoblasts but not on mature cells by increasing their susceptibility to apoptosis. Apoptosis occurs in a caspase-dependent manner as both DNA fragmentation and mitochondrial transmembrane potential dissipation (~\f'm) are inhibited by the pan-caspase inhibitor zVAD. The increased susceptibility of osteoblast precursors to apoptosis could be due to dexamethasonemediated down-regulation of survivin expression. Dexamethasone can up-regulate survivin, and to a lesser extent Bcl-2, in mature cells but not in pre-osteoblasts. In addition, it can induce FLIP over-expression in. osteosarcoma cells. All these effects are inhibited by the glucocorticoid antagonist RU486, indicating that dexamethasone action is specific and, furthermore, that it depends on glucocorticoid receptor. Finally, we have found that survivin and Bcl-2 are essential for pre-and mature osteoblast survival as their silencing is sufficient to induce spontaneous apoptosis in both cell types. In conclusion, our data outline a new molecular mechanism of glucocorticoid-mediated bone loss due to the enhanced apoptosis of precursors compared to mature osteoblasts. Furthermore, the data suggest a mechanism of dexamethasone-induced resistance of osteosarcoma cells to Fas-and stress-induced apoptosis.
transient increase in bone resorption caused by the GC-induced prolongation of pre-existing osteoclasts lifespan (4) (5) (6) . The second phase is characterized by progressive bone loss due to impaired bone formation. Such phenomenon includes: GC-induced suppression of osteoblastogenesis (7) (8) ; arrest of osteoclast-mediated bone resorption which, in turn, translates into dampened osteoblast activity (9) ; and a pro-apoptotic effect on osteoblasts and osteocytes (8, (10) (11) (12) (13) . Under GC treatment murine osteoblasts die following a programmed cell death mechanism mediated by caspases (14) (15) , even though the mechanism is unclear.
Apoptosis can be induced by death receptormediated extrinsic pathways, such as Fas, or by stress-induced intrinsic pathways, such as serum withdrawal or oxidative damage (16) .
Fas is a death receptor belonging to the Tumor Necrosis Factor Receptor (TNFR) family. Fas and its ligand (FasL) represent a molecular system playing an important role in normal tissue homeostasis which can be altered in pathological conditions, such as autoimmune diseases and cancer (17) (18) (19) (20) . Both extrinsic and intrinsic pathways trigger apoptosis by activating the caspase proteolytic cascade. Caspase-3 activation is a later common event occurring predominantly after mitochondrial transmembrane potential dissipation (il'Pm). il'Pm allows the release of pro-apoptotic factors responsible for the propagation of the apoptotic signal (21) . The proapoptotic cascade can be blocked at different levels by apoptosis inhibitors. FLIP inhibits caspase-8 activation following death receptor triggering, Bcl-2 acts at the outer mitochondrial membrane blocking the il'Pm, whereas survivin inhibits the apoptotic signal at a post-mitochondrial phase by inhibiting effector caspases (22) (23) (24) (25) .
Human osteoblasts and mesenchymal stem cells (MSCs) have functioning Fas, even though under conditions favouring cell growth in vitro, this receptor cannot trigger apoptosis (26) (27) . Furthermore, it has been shown that FasL plays a role in the inhibition of osteoblast differentiation (28) , but a potential role ofFas triggering on human osteoblast precursors and mature osteoblasts apoptosis under GC treatment has been very poorly investigated.
The aim ofthis study was to analyse and compare the susceptibility of normal human osteoblast precursor cells and mature osteoblasts to Fas-and stress-induced cell death under GC treatment and the molecular mechanisms involved. Furthermore, as dexamethasone-treated osteosarcoma cell resistance to Fas-induced cell death has been previously described (29) , we also analysed the differences between normal cells and cancer cells.
The results obtained may be useful to elaborate new preventive and therapeutic strategies for glucocorticoid-induced bone loss.
MATERIALS AND METHODS

Cell cultures and treatments
The human osteoblastic cell line hFOB 1.19 was purchased from the American Type Culture Collection ATCC (Rockville, MD, USA) and cultured in a medium containing I: I mixture of Dulbeccos's Modified Eagle's Medium (ATCC) and Ham's FI2 medium (ATCC) with 2.5 mM L-Glutamine, 15 mM HEPES, 0.5 mM sodium pyruvate, 1.2g/L sodium bicarbonate (all from Euroclone, Italy), 10% fetal bovine serum (FBS) (Gibco, Invitrogen Life Technologies, Carlsbad, CA, USA) and 0.3 mg/ml G418 (SIGMA-ALDRICH Inc. Italy). Cells were grown at a permissive temperature of 35°C as osteoblast precursor cells (hFOB-35), or at a restrictive temperature of 39.5°C (hFOB-39.5) which allows cell differentiation into a mature osteoblast phenotype (30) . hFOB characterization: h-FOB cells were stained for positive Von Kossa and Alkaline Phosphatase and FACS® analysed for osteocalcin. Osteoblast precursors (hFOB-35) were also characterized for CD73, CD90, CDl05 CD45, HLA-DR and CDI4 expression by FACS® analysis. Furthermore, Runx2 and osteocalcin mRNA levels were quantified by Real Time-PCR in both pre-and mature osteoblasts,
Von Kassa staining
Fixed cells were rinsed in distilled water and then treated with a 5% silver nitrate solution for I hour under sunlight. After washing in distilled water, cells were incubated in 1% pirogallic acid for 3 min, then washed again and incubated in 5% sodium tiophosphate for I min. Calcium salts appear black (all reagents used were from SIGMA-ALDRICH).
Alkaline phosphatase staining
Cells were covered with stain solution (100 rnM TRIS, 100 mM NaCI, 5 rnM MgCI 2 • Nitro Blu Tetrazolium, 5-Bromo-4-Chloro-3-Indolyl Phosphate and Levamisole) for 12 h at room temperature. To stop the reaction, PBS containing 20 rnM EDTA was added. Positive cells were blue stained (all reagents used were from SIGMA-ALDRICH).
FAC~analysis
Fixed cells were stained with the anti-human osteocalcin monoclonal antibody OC I (Biodesign Int. Industrial Park Road, Saco, ME), the anti-CD73-PE (BD Biosciences Pharmingen, San Diego, CA, USA), the anti-CD90-FITC (Stemcell Technologies, VANCOUVER, British Columbia), the anti-CDI05-FITC, CD45-PE, HLA-DR-PE and CDl4-FITC (Diaclone Research, Cell Sciences, Canton, MA).
RT-PCR
Total cellular RNA was isolated from cells using OMNIZOL Total RNA isolation kit (Euroclone Ltd, UK) according to the manufacturer's instructions. The RNA concentration and purity were determined by Nanodrop ND-IOOO spectrophotometer (NanoDrop Technologies Inc, USA). Total RNA (500 ng) was reversely transcribed with Omniscript Reverse Transcriptase (Qiagen, Germany, Europe) according to the manufacturer's specification and using random octamers. Resulting cDNA (final volume of 20 Ill) was kept at -80°C until further utilization. Realtime PCR analyses were performed on a DNA Engine Opticon 4 System (MJ Research; Reno, NV, USA) using the iQ-SYBR(r) Green Supermix (BioRad Laboratories, CA, USA) premixed PCR reagents. Primers sequences for RUNX2 were:~'TCTTCCCAAAGCCAGAGTG3; CATGGGAAACTGATAGGATCCJ' and for Osteocalcin were:~'GGCAGCGAGGTAGTGAAGAG; CTGGAGAGGAGCAGAACTGGJ'. All primers were synthesized by Invitrogen Corporation (UK). The PCR conditions were 95°C for 3 min, then 40 cycles at 95°C for 10 sec, 60°C for 20 sec and noc for 30 sec.
The human osteosarcoma cell line MG63 was purchased from ATCC and cultured in Minimum Essential Medium Eagle (ATCC), supplemented with 10% heatinactivated FBS, 1% L-glutamine and I% penicillin! streptomycin.
Dexamethasone (1O-7M) and RU486 (l0-6M) were both purchased from SIGMA. The pan-caspases inhibitor zVAD-frnk (20 11M) was purchased from Alexis Biochemicals (ENZO Life Sciences Inc, Plymouth Meeting, PA, USA).
To induce apoptosis, cells were treated with 500ng/ml of the anti-Fas agonistic antibody CH-II (UBI, Lake Placid, NY, USA) or they were cultured in absence of serum.
Evaluation ofapoptosis
Apoptosis was evaluated by cytofluorimetric analysis of both propidium iodide (PI) (SIGMA) stained hypodiploid nuclei and of mitochondrial transmembrane potential dissipation (~'Pm) of cells stained with the fluorochrome JC-I (Molecular Probes, Invitrogen Life Technologies). JC-I is a cationic dye that indicates mitochondrial polarization by shifting its fluorescence emission from green to red. After treatments, cells were harvested, transferred to FACS tubes and processed as briefly described below. For PI staining they were washed with PBS and then resuspended in phosphate-buffered saline containing 50Ilg/ml PI, 0.1% Triton X-IOO (SIGMA) and 0.1% sodium citrate (Merck, Whitehouse Station, NJ, USA). Samples were stored at 4°C in the dark for 5 h and then analyzed by BD FACSCalibur® cytometer (BD Biosciences, NJ, USA). For JC-I staining cells were resuspended in fresh medium, incubated for I h with O.3llg/ml JC-I, washed twice with PBS and analysed to detect the fluorescence emitted by JC-I-monomer and JC-I-aggregate in FLI and FL2 channels, respectively. The percentage of cells with depolarised mitochondria was calculated as the percentage of events with increased FLI fluorescence.
Western blot analysis
Harvested cells were re-suspended in lysis buffer (1% Triton 100X, 150 mM NaCI, 10 mM Tris pH7.4, I mM EDTA pH8, Sug/ml aprotinin, 0.71lg/ml pepstatin, Sug/ml leupeptin, I mM phenylmethylsulfonyl fluoride), incubated for 40 min on ice and centrifuged at 14000 rpm for 15 min at 4°C. The supernatants were collected and the protein concentration was determined by the standard Bradford protein assay (Bio-Rad). 40 ug of proteins for each sample were separated by 12% SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were blocked in TBS containing 5% non-fat dry milk and then probed for 2 h at room temperature with the primary antibodies antisurvivin (I: 1000; Novus Biologicals, CO), anti-Bcl-2 (I: 500; Cell Signaling Technology, MA, USA), anti-FLIP (I :500, Alexis Biochemicals), anti-pro-caspase-S (BD, Pharmingen, San Diego, CA, USA) and anti-pro-caspase-3, clone 3G2 (Cell Signaling Technology, Danvers, MA, USA). After being extensively washed in TBS with 0.1% Tween-20 membranes were incubated for 45' with horseradish peroxidase-conjugated goat anti-rabbit (Chemicon, Temecula, CA, USA) or rabbit anti-mouse (SIGMA) secondary antibodies. Immunoreactivity was detected by chemiluminescence LiteAblot, (Euroclone) and visualized by autoradiography. All Western blots were re-probed with anti-human actin antibody (I: 20000) (Calbiochem, MERCK Chemicals) to confirm the equivalent loading of all samples.
Fas and FasL expression analysis
Membrane Fas expression and FasL total expression were detected by flow cytometry (FACSCalibur®, BD Biosciences) using the anti-human Fas (clone DX2, kindly provided by Dr Roberto Testi, University of Rome Tor Vergata) and the anti-human FasL 5G51 (Alexis) primary antibodies and then FITC-conjugated anti mouse IgG (Sigma-Aldrich). Briefly, for FasL immunostaining cells were fixed in 4% paraformaldehyde for 15 min, washed with PBS and permeabilized with PBS containing 1% BSA and 0.1% Triton X-IOO for 15 min. Cells were then incubated in PBS/I %BSA for 45 min at 4°C with the primary antibodies, washed twice with PBS and incubated for 20 min at 4°C in the dark with the FITC-conjugated secondary antibody.
Bcl-2 and survivin silencing
Oligos for the different shRNA were cloned into HpaI-XhoI-digested pLL3.7 vector. The following target regions were selected: Survshl 5'GCATCTCTACATTCAAGAA-3' (survivin); Bcl2sh2 -5' -GGGAGATAGTGATGAAGTA-3' (BcI-2).
Lentiviral production was performed as previously described (31) . Briefly, lentiviral virions were produced by co-transfecting 293T cells with 16 ug of pLL3.7-Survshl or pLL3.7-Bcl2sh2 (pLL3.7 empty vector as control) in combination with packaging VSVG (8 ug) and~8.2 (12 mg) plasmids. Supernatants of transiently transfected 293T cells were harvested after 36 hand filtered (0.45 urn); two cycles of infection were performed (6 h each cycle) within 24 h for hFOB-35, hFOB-39.5 and MG63 cells. Forty-eight hours after infection cells were harvested and EGFP positivity was monitored by FACS analysis to verify the efficiency of infection that was about 95% of total cells. Cells were then processed for propidium iodide staining and western blot analysis.
Statistical analysis
Student's t-test was used to evaluate significant differences between the percentage of apoptotic cells at different conditions of treatment. P-values p:S 0.05 were considered statistically significant. To determine whether protein expression, analysed by flow cytometry, significantly differs between two samples, the Kolmogorov-Smirnov test, automatically performed by the FACS instruments, was used. Again P-values p:S 0.05 were considered statistically significant.
RESULTS
Fas and FasL expression in human pre-osteoblasts and mature osteoblasts
The expression of Fas and FasL was investigated in immature and mature hFOB cells. The human foetal cell line hFOB 1.19 was cultured at 35°C as osteoblast precursors (hFOB-35) or was induced to differentiate into mature osteoblasts at a restrictive temperature of 39.5°C (hFOB-39.5), as recently published (30) . The differentiation stage was checked by Von Kossa and ALP staining, by detection of Runx2 and osteocalcin mRNA levels and by cytofluorimetric analysis of mesenchymal stem cell markers (data not shown, see material and methods). Both hFOB-35 and hFOB-39.5 cells expressed Fas at the membrane level but its expression was found to be increased in mature osteoblasts ( Fig. I, left panel) and maintained stable after 7 days of culture (data not shown). Fas expression in hFOB-39.5 cells was comparable to that of human MG63 osteosarcoma cells ( Fig. I, left panel) . FasL expression could not be observed in non-fixed and non-permeabilized hFOB 1.19 cells (data not shown), suggesting its absence or very low expression on the cell surface. However, permeabilized hFOB-35, hFOB-39.5 and MG63 cells were positively stained with the anti-FasL (Fig. 1, right panel) . Nevertheless, non-toxic doses (l0·7M) of dexamethasone had no effect on Fas and FasL expression both in undifferentiated and mature osteoblasts (data not shown).
Dexamethasone sensitizes pre-osteoblasts but not mature osteoblasts to Fas-induced cell death
Given that Fas is differently expressed in pre-and mature osteoblasts, the effect of dexamethasone on Fas-induced cell death was analysed at both stages of differentiation. As shown in Fig. 2A , both hFOB-35 and 39.5 cells were slightly susceptible to Fasinduced apoptosis triggered by the anti-Fas agonistic antibody CH 11 for 48 hours. Dexamethasone (l0·7M) alone did not have a pro-apoptotic effect. However, it significantly sensitized hFOB-35 cells to Fas-induced apoptosis when it was added 48 hours before Fas stimulation (p:'SO.O 1) ( Fig. 2A,  left panel) . Surprisingly, dexamethasone did not increase Fas-induced cell death of hFOB-39.5 cells but it even seemed to slightly reduce the percentage of apoptotic cells ( Fig. 2A, right panel) , whereas it inhibited apoptosis in MG63 osteosarcoma cell line which underwent the same treatment (p<O.OI) (Fig. 2B ). The apoptotic process was mediated by caspases, as it was inhibited by the pan-caspase inhibitor zVAD, which was added 30 minutes before Fas stimulation ( Fig. 2A) .
To determine whether mitochondria were involved in apoptosis, the mitochondrial transmembrane potential dissipation (A'Pm) was assayed: again, pre-treatment with dexamethasone enhanced Fas-induced~'¥m ( Fig. 2C ) in hFOB-35 cells, but not in hFOB-39.5 cells. Also this process appeared to be mediated, at least partially, by caspases as it was inhibited by zVAD.
Dexamethasone affects caspases activation during Fas-induced apoptosis ofhFOB cells
The molecular mechanisms involved in apoptosis of osteoblasts and their precursor cells were more deeply investigated. To this purpose, hFOB-35, hFOB-39.5 and MG63 cells were left untreated or pre-treated with dexamethasone and then stimulated with the anti-Fas antibody for 48 hours to measure caspase activation. As shown in Fig. 3A , Fas stimulation induced a stronger processing of caspase-8 and -3 in mature cells (hFOB-39.5 and MG63) compared to their precursors (hFOB-35). However, dexamethasone increased Fas-induced pro-caspase-8 and, more strongly, pro-caspase-3 processing in hFOB-35 cells, whereas it inhibited their activation in hFOB-39.5 and MG63 cells. This pattern of caspase activation is in keeping with cellular susceptibility to apoptosis ( Figs. 2A and 2B ). Furthermore, caspase processing in all three cell systems was inhibited by zVAD indicating their specific activation. 
Dexam ethasone modulates survtvtn expression in pre-and mature osteoblasts in an opposite manner
The expression ofthe anti-apoptotic proteins FLIP, Bcl-2 and survivin was analysed in untreated and Dex-treated hFOB-35 , hFOB-39 .5 and MG63 cells in order to investigate the mechanisms responsible for dexamethasone-mediated sensitization of osteoblast precursors to apoptosis and, furthermore , the different behaviour of mature osteoblasts and osteosarcoma cells compared to pre-osteoblasts.
As shown in Fig. 3B , survivin was highly expressed in hFOB-3 5 cells but its expression was markedly down-regulated by dexamethasone treatment. Conversely, survivin was less expressed in untreated hFOB-39.5 and MG-63 cells compared to untreated hFOB-35 cells, but it was markedly up-regulated in the presence of dexamethasone (Fig. 3B ). Protein expression correlated with survivin mRNA levels analysed by real-time PCR (data not shown). Bcl-2 was also up-regulated by dexamethasone in hFOB-39.5 and MG-63 cells, whereas FLIP expression remained unchanged in both hFOB-35 and hFOB39 .5 cells but increased in MG63 osteosarcoma cells .
RU486 antagonizes the effects ofdexameth asone on apoptos is and anti-apoptotic protein expression of osteoblastic cells
To determine whethe r the effects of dexamethasone on both anti-apoptotic protein expression and sensitization to apoptosis were specific, the selective glucocorticoid antagonist RU486 was used to block the action of dexamethasone (32) (33) . In hFOB-35 cells the pre-treatment with RU486 (lO·6M for 24 h) inhibited dexamethasone-induced decrease in survivin expression ( Fig. 4A, right panel) and was accordingly able to partially abolish the pro-apoptotic effect of dexamethasone in Fas-induced cell death (p<O.O I) (Fig. 4A, left panel) . On the other hand, the effect of RU486 pre-treatment on hFOB-39.5 and MG63 cells was to inhibit dexamethasone-induced survivin and further Bcl-2 over-expression ( Fig. 4B and C, right panel), thus abolishing its anti-apoptotic effect ( Fig. 4B and C, left panel) .
Dexamethasone affects the sensitivity ofosteoblasts and their precursors to serum withdrawal-induced . cell death
After testing the modulatory effect of dexamethasone on both survivin and Bcl-2 expression and on the extrinsic pathway-induced apoptosis (Fig. 3B) , the serum deprivation-induced apoptosis was tested. Cells, pre-treated with either dexamethasone or RU486 alone or a combination of both, were cultured in the presence or absence of serum. As shown in Fig. 5 , all cell lines, hFOB-35 (A), hFOB-39.5 (B) and MG63 (C) showed an induction of apoptosis at 48 hours of serum deprivation. However, whilst pre-treatment with dexamethasone alone seemed to confer a slight protective effect on serum deprivation-induced cell death of h-FOB mature cells and more strongly of MG63 ( Fig. 5B and C, respectively) , it strongly sensitized pre-osteoblasts to cell death (Fig. 5A) .
Furthermore, RU486 antagonized the effect of dexamethasone as it did in the case of Fas-induced apoptosis. Interestingly, RU486 pre-treatment alone, which induced survivin and Bcl-2 over-expression in MG63 cells (Fig. 4C) conferred protection from serum deprivation as well as dexamethasone treatment alone.
B
Survivin and Bcl-2 are necessaryfor pre-and mature osteoblast survival To determine whether survivm and Bcl-2 play a key role in the survival of both osteoblast precursors and mature osteoblasts, Bcl-2 and survivin expressions were alternatively suppressed with specific shRNAs (Survsh 1 and Bcl2sh2). The efficiency of infection was very high in both hFOB-35 and hFOB-39.5 cells ( Fig. 6A and B , left panels) but unfortunately, it was very low in MG63 osteosarcoma cells (data not shown). As expected, both survshl and Bcl-2sh2 efficiently suppressed the protein expression of survivin and Bcl-2 respectively in hFOB ( Fig. 6A and B ), but not in MG63 cells (data not shown). Surprisingly, Bcl-2 suppression strongly decreased survivin expression, while the reverse phenomenon was not observed. More importantly, both proteins proved to be necessary to survival of both precursor and mature cells, since a significant amount of cells spontaneously died after survivin and Bcl-2 silencing ( Fig. 6A and B , right panels). Glucocorticoid-induced bone loss IS characterised by the alteration of osteoblast lifespan through regulated apoptosis. This work compared the effect of dexamethasone on pro-apoptotic extrinsic (Fas) and intrinsic (serum deprivation) pathways on osteoblastic cells at two different stages of differentiation (pre-osteoblasts and mature osteoblasts). The results obtained provide new information in this field: firstly, they suggest a new molecular mechanism of glucocorticoid-mediated bone loss based on the ability of dexamethasone to sensitise human pre-osteoblasts to pro-apoptotic stimuli rather than differentiated cells; secondly, they highlight the importance of several anti-apoptotic proteins in osteoblastic cell survival and their role in dexamethasone-mediated apoptosis. 
EGFP positivity was analysed by FACS to check infection efficiency (thin curves represent uninfected cells, thick curves represent infected cells) (A and B, left panels). Survivin and Bcl-2 expression levels were analysed by Western blot and their relative effect on apoptosis is represented~s percentage ofcells with hypodiploid nuclei (right panels). The percentage ofapoptotic cells represents the average ofthree independent experiments.
The human osteoblastic cell line hFOB 1.19 was used, which represents a validated experimental system to study mesenchymal progenitors. However, hFOB 1.19 cultured at 35°C were considered as osteoblast precursors rather than stem progenitors, since they expressed several differentiation markers (Runx2 and osteocalcin, data not shown) in addition to stem cell markers.
In accordance with the published data, this study shows that dexamethasone alone does not have a pro-apoptotic effect on precursor cells of mesenchymal origin, whereas Fas induces a small but significant increase in the number of apoptotic cells. The same phenomenon is observed in mature osteoblasts. However, the pre-treatment of cells with dexamethasone strongly sensitizes osteoblast precursors to Fas-induced apoptosis contrary to which occurs, unexpectedly, for mature osteoblasts, which express higher Fas levels (Fig. 1, left panels) .
The resistance of mature osteoblasts to Fasinduced cell death under glucocorticoid treatment was previously described on the human MG63 osteosarcoma cell line by Nakashima et al. However, such resistance has not been found to have a molecular explanation (29) . These observations led the study to compare the effect ofdexamethasone on the expression of anti-apoptotic proteins not only in undifferentiated and differentiated hFOB cells but also in MG63 cancer cells. It emerged that in absence of dexamethasone basal FLIP and survivin expression levels are lower in mature osteoblasts and MG63 cells than in precursor cells (Fig. 3B ). However, dexamethasone has a different effect on anti-apoptotic protein expression, depending on the cellular differentiation stage: it strongly down-regulates survivin in pre-osteoblasts but has the opposite effect on mature cells and MG63 cells. Dexamethasone-mediated survivin downregulation correlates with the stronger activation of caspase-3 in precursor cells upon Fas triggering. On the other hand, dexamethasone-mediated survivin up-regulation correlates with caspase-3 inhibition in mature cells. The resistance to apoptosis (Figs. 2 and 5) and the inhibition of both caspase-8 and -3 activation in dexamethasone-pre-treated mature osteoblasts can be further explained by the up-regulation of Bcl-2. In addition, it must be noted that FLIP is up-regulated in osteosarcoma MG63 cells (Fig. 3B) , which are strongly protected from cell death by dexamethasone (Figs. 2B, 5C ).
The effects of dexamethasone on apoptosis and on survivin and Bcl-2 expression are antagonized by RU486 indicating that the effect of dexamethasone is specific ( Fig. 4 and Fig. 5 ) and, furthermore, that it is glucocorticoid receptor dependent. However, a paradoxical effect of RU486 alone has been observed on the up-regulation of survivin and Bcl-2 expression in MG63 cells. This phenomenon has been previously described and analysed in osteosarcoma cells by Fryer and co-worker (34) which show that in osteosarcoma cells the antiglucocorticoids RU486 and RU43044 exhibit partial agonistic activity.
Furthermore, as shown in other cellular systems, both survivin and Bcl-2 are essential for survival of normal osteoblastic cells as their single silencing induces spontaneous apoptosis of hFOB at both stages of differentiation ( Fig. 6  A and B) . Nevertheless, there is no evidence that survivin and Bcl-2 playa similar fundamental role in osteosarcoma cancer cells, as their silencing in MG63 was not successful due to poor lentiviral infection rate (data not shown).
Taken together, these data contribute to elucidate the anti-apoptotic pathways involved in osteoblast precursors and mature osteoblast survival. More importantly, they give suggestions on the apoptotic pathways activated in these cells by Fas or stressing conditions (serum deprivation) in presence of glucocorticoid. Survivin modulation by glucocorticoid seems to be one of the molecular mechanisms switching on/offapoptosis. In particular, the results suggest that GCs sensitize pre-osteoblast to apoptosis via survivin down-regulation. In light of our results, we propose that GCs may influence bone loss not only by inhibiting osteoblastogenesis (8) , but also sensitizing osteoblast precursors to intrinsic and extrinsic apoptotic pathways.
Our data could be useful in designing new preventive strategies to avoid bone loss and to devise new experimental and innovative cellular therapies to dampen the effect of long-term GC treatment. In addition, they partially show the molecular mechanisms involved in dexamethasone-induced resistance to apoptosis of osteosarcoma cells.
